Logo Image
|Peer-Reviewed|December 24, 2020

Evidence-Based Oncology

  • February 2021
  • Volume 27
  • Issue 2

Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.

eAPPENDIX Cost of Home vs Clinic Administration of Paclitaxel in mBC

Articles in this issue

over 5 years ago

Use of COTA Nodal Address Highlights Variance in Cancer Care Cost: An Interview With Donald M. Berwick, MD, MPP

over 5 years ago

Radiation Oncology’s Role in the Next Chapter of Payment Reform

over 5 years ago

ACCC and ASCO Collaborative Targets Disparities in Cancer Clinical Trials

over 5 years ago

Flying the Plane While You Build It

over 5 years ago

The Untapped Potential of Cell and Gene Therapy

over 5 years ago

Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel

over 5 years ago

FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC

over 5 years ago

Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show

over 5 years ago

Possible Treatment Identified for Aggressive NSCLC Subset

over 5 years ago

Contributor: A Practical Path Forward to More Patient-Centered Value Assessment

Related Content